Ninety One UK Ltd Sells 17,268 Shares of Veeva Systems Inc. $VEEV

Ninety One UK Ltd lessened its position in shares of Veeva Systems Inc. (NYSE:VEEV) by 26.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 48,346 shares of the technology company’s stock after selling 17,268 shares during the period. Ninety One UK Ltd’s holdings in Veeva Systems were worth $13,800,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Principal Financial Group Inc. grew its stake in shares of Veeva Systems by 7.0% during the 1st quarter. Principal Financial Group Inc. now owns 4,141,545 shares of the technology company’s stock worth $727,513,000 after acquiring an additional 271,252 shares during the period. Swedbank AB increased its holdings in Veeva Systems by 43.5% in the 1st quarter. Swedbank AB now owns 1,645,128 shares of the technology company’s stock worth $288,983,000 after acquiring an additional 498,971 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in Veeva Systems by 43.6% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,593,795 shares of the technology company’s stock valued at $279,970,000 after acquiring an additional 483,720 shares during the period. Amundi boosted its position in shares of Veeva Systems by 8.0% during the 1st quarter. Amundi now owns 992,977 shares of the technology company’s stock valued at $174,426,000 after acquiring an additional 73,510 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Veeva Systems by 203.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 913,281 shares of the technology company’s stock valued at $160,427,000 after acquiring an additional 611,868 shares during the last quarter. Institutional investors own 88.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VEEV. Canaccord Genuity Group upped their price objective on shares of Veeva Systems from $220.00 to $260.00 and gave the stock a “hold” rating in a research report on Thursday, August 27th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $330.00 target price on shares of Veeva Systems in a research note on Tuesday, September 8th. Oppenheimer reiterated an “outperform” rating and set a $325.00 target price on shares of Veeva Systems in a research report on Thursday. Needham & Company LLC boosted their price target on shares of Veeva Systems from $270.00 to $310.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Finally, Guggenheim boosted their price target on shares of Veeva Systems from $276.00 to $310.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Nineteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Veeva Systems presently has an average rating of “Moderate Buy” and an average target price of $285.92.

Insider Activity

In related news, EVP Daniel Rizzo sold 4,841 shares of the firm’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $276.51, for a total transaction of $1,338,584.91. Following the transaction, the executive vice president directly owned 7,665 shares of the company’s stock, valued at approximately $2,119,449.15. This trade represents a 38.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Priscilla Hung sold 750 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $261.04, for a total value of $195,780.00. Following the transaction, the director directly owned 3,242 shares in the company, valued at approximately $846,291.68. This represents a 18.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 51,591 shares of company stock worth $13,355,945. 10.60% of the stock is currently owned by insiders.

Veeva Systems News Roundup

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Expanded IQVIA partnership strengthens Veeva’s clinical-software position. IQVIA selected Veeva’s Clinical Trial Management System, eTMF, Study Startup, and Site Connect applications as enterprise standards across its global clinical studies. The agreement expands Veeva’s footprint with a major contract research organization and could support broader adoption among biopharma customers. Veeva Systems Becomes Default Clinical Software Across a Major Research Partner
• Positive Sentiment: Analyst support remains favorable. Oppenheimer maintained a $325 price target, and average brokerage recommendations remain optimistic. While analyst ratings can be biased, the continued positive stance is supporting investor confidence. Oppenheimer Keeps USD 325 Target for Veeva Systems Stock
• Positive Sentiment: Technical momentum attracted additional buying. Veeva moved above a buy point in an early-stage chart pattern, with reports describing increased institutional or “big money” exposure to the AI and life-sciences software theme. Veeva Stock Breaks Out as Big Money Grabs Exposure
• Positive Sentiment: Veeva’s growth platform continues to broaden. More than 175 emerging biotechs reportedly use Veeva Basics, adding to the company’s clinical, regulatory, and quality software ecosystem. Veeva also plans to hold a virtual investor day on November 5, which could provide additional detail on strategy and growth opportunities. Veeva to Host Virtual Investor Day
• Neutral Sentiment: Veeva is receiving elevated investor attention, and industry forecasts point to long-term expansion in life-sciences IT driven by cloud and artificial-intelligence adoption. These factors support the broader investment narrative but do not represent new company-specific revenue.
• Negative Sentiment: Oppenheimer noted that Veeva’s guidance may imply further deceleration in research-and-development growth. This could temper expectations and remains a risk for a stock trading at a premium valuation. Veeva Systems’ Research and Development Growth Tracking to Plan

Veeva Systems Stock Up 5.3%

VEEV opened at $313.01 on Friday. The business’s fifty day simple moving average is $268.19 and its 200 day simple moving average is $207.22. Veeva Systems Inc. has a 52 week low of $148.05 and a 52 week high of $315.02. The stock has a market cap of $50.68 billion, a PE ratio of 51.48, a P/E/G ratio of 1.27 and a beta of 0.93.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.23 by $0.12. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%. The firm had revenue of $927.96 million during the quarter, compared to analyst estimates of $905.38 million. During the same quarter in the previous year, the company posted $1.99 earnings per share. The company’s revenue was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. As a group, equities analysts anticipate that Veeva Systems Inc. will post 6.70 earnings per share for the current year.

Veeva Systems Company Profile

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.